reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Interpace Biosciences, Inc.

IDXG · OTC

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$3Mpublic float
2025-03-06most recent failure
2025-03-06declared past accounts unreliable

Score over time

012202220232024202520262022-01-01 · score 12021-04-01 filed late (10-K) · accounts not ready2022-04-01 · score 12021-04-01 filed late (10-K) · accounts not ready2022-07-01 · score 12022-04-14 auditor change2022-10-01 · score 12022-04-14 auditor change2023-01-01 · score 12022-04-14 auditor change2023-04-01 · score 12022-04-14 auditor change2025-04-01 · score 12025-03-06 accounts unreliable2025-07-01 · score 12025-03-06 accounts unreliable2025-10-01 · score 12025-03-06 accounts unreliable2026-01-01 · score 12025-03-06 accounts unreliable

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Interpace Biosciences, Inc.’s (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2020 cannot be filed within the prescribed time period because the Company requires additional time to complete its audited financial statements. The Company expects that its Annual Report on Form 10-K for the year ended December 31, 2020 will be filed on or before the 15th calendar day following the prescribed due date. Forward Looking Statements This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, the Company’s expectations as to the filing of its Annual Report on Form 10-K for the year ended December 31, 2020.These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management’s current expectations include the risk that the Company will be unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 within the extension period of 15 calendar days provided under Rule 12b-25 of the Exchange Act. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this filing and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason

NT 10-K, filed 2021-04-01 · accounts not ready

What it filed

2025-03-06accounts declared unreliable SEC →

2022-04-14auditor changed or resigned SEC →

2021-04-01filed late (10-K)accounts not ready SEC →

Interpace Biosciences, Inc.’s (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2020 cannot be filed within the prescribed time period because the Company requires additional time to complete its audited financial statements. The Company expects that its Annual Report on Form 10-K for the year ended December 31, 2020 will be filed on or before the 15th calendar day following the prescribed due date. Forward Looking Statements This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, the Company’s expectations as to the filing of its Annual Report on Form 10-K for the year ended December 31, 2020.These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management’s current expectations include the risk that the Company will be unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 within the extension period of 15 calendar days provided under Rule 12b-25 of the Exchange Act. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this filing and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com